COVID-19 (coronavirus disease 2019) is a respiratory tract infection with a newly recognized coronavirus, SARS-CoV-2, thought to have originated as a zoonotic virus that has mutated or otherwise adapted in ways that allow human pathogenicity
Mild disease: Symptomatic patients with suspected, probable, or confirmed SARS-CoV-2 infection without evidence of viral pneumonia or hypoxia
MIS-C (multisystem inflammatory syndrome in children) is a recently described clinical syndrome in children and adolescents, originally recognized in temporal association with a high local prevalence of COVID-19 (coronavirus disease 2019).
MIS-C is a rare and novel disease; therefore, it is not yet possible to make firm evidence based recommendations. Rigorous data to guide most diagnostic and management strategies is lacking and optimal treatment is unknown.
User acknowledges that these COVID-19-related materials are provided for use at no charge as part of Elsevier’s efforts to support healthcare providers and patients. The information contained within the website is intended as a supplement to, and not a substitute for, the knowledge, expertise, skill and judgment of healthcare professionals involved in patient care. The content within this page may not be re-used, modified or re-distributed without prior written permission.
Cookies are used by this site. To decline or learn more, visit our cookie notice.
Copyright © 2024 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.